The APOH knockout A-549 polyclonal cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line. CRISPR/Cas9-mediated gene disruption has been employed to inactivate the APOH locus, generating a heterogeneous pool of loss-of-function mutants. This polyclonal format mitigates clonal selection effects and provides a robust model for studying APOH-dependent processes while retaining the key phenotypic properties of the parental A-549 cells.
The A-549 cell line, established from a lung carcinoma of a 58-year-old Caucasian male, serves as a widely used model in cancer biology and drug development. These adherent epithelial cells exhibit type II alveolar characteristics and are valued for their reproducible growth and responsiveness to experimental stimuli. The lung cancer origin offers a disease-relevant cellular context for investigating the functional consequences of APOH knockout.
APOH encodes beta-2-glycoprotein I (??2GPI), a phospholipid-binding protein integral to coagulation and lipid homeostasis. ??2GPI directly interacts with anionic phospholipids, cardiolipin, coagulation factor XII, prothrombin, and annexin A5, and its expression is transcriptionally regulated by HNF1A, HNF4A, PPARG, and IL-6. As a cofactor for anti-phospholipid antibodies, ??2GPI promotes platelet activation through receptors GP Ib/IX/V and GPVI, upregulates tissue factor, and triggers complement C3 deposition, linking innate immunity to thrombosis.
In the A-549 adenocarcinoma background, APOH knockout eliminates ??2GPI expression, enabling dissection of its role in cancer-associated coagulation and inflammation. Although A-549 cells are not primary hemostatic cells, they express tissue factor and can be induced to exhibit procoagulant activity. This knockout model allows for the study of tumor-driven thrombotic mechanisms, platelet?Ctumor cell interactions, and the contribution of ??2GPI to the tumor microenvironment, with direct relevance to antiphospholipid syndrome and thrombosis in cancer.
Applications include Western blot validation of knockout, anti-??2-glycoprotein I ELISA, and flow cytometry to assess phospholipid binding. Cell-based coagulation assays evaluate functional consequences, while migration and invasion assays probe ??2GPI??s role in tumor cell behavior. Transcriptomic analyses via RNA-seq and RT-qPCR further characterize pathway alterations, and the model supports drug target validation for thrombotic diseases. For additional details, please contact Ascent Research.
